1O'shangehnessg J, Miles D, Vukelja S,et al. Superior survival with capecitaline plus docetaxel combination therapy in anthracyeline-pretreated patients with advanced breast cancer: phase Ⅲ trial results[ J]. J Clin Oncol,2002,20:2812-2823.
2Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[ J]. J Clin Oncol, 1999,17:485-493.
4Figgitt DP, Wiseman LR. Docetaxel: an update of the use in advanced breast cancer[J]. Drugs,2000,59:621-651.
5Blum JL,Dieras V,LoRuso P,et al. Multicenter,phase II study of capecitaline in taxane-pretreated metastatic breast carcinoma patients[ J]. Cancer, 2001,92 : 1759-1768.
5Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in multidrug resistant human lung cancer cell line. Science, 1992, 258: 1650-1654.
6Scheper R J, Broxterman H J, Scheffer GL, et al. Overexpression of a M (r) 110 000 vesicular protein in non-P-glycoprotein-meidiated multidrug resistance. Cancer Res, 1993, 53: 1475-1479.
7Xu BH, Singh SV. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mltomycin C analogues BMY 25282 and BMY 25067. Cancer Res, 1992, 52 : 6666-6670.
8Xu BH, Gupta V, Singh SV. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. Int J Cancer, 1994, 58 : 686-692.
9Maiche AG, Jekumen AP, Kaleva-Kerola J, et al. High response rate with a lower dose of paclitaxel in combination with cispaltin in heavily pretreated patients with advanced breast carcinoma. Cancer, 2000, 88: 1863-1868.
10Airoldi M, Cattel L, Pedani F, et al. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycine resistant/relapsed metastatic breast cancer. Acta Oncol, 2003, 42: 186-194.
2Blum JL, Dieras V, Lo Ruso P M, et al. Multicenter phase 11 study of capecitaline in taxane-pretreated metastatic breast carcinoma patients[J]. Cancer, 2001, 92:1759-1768.
